CNS disorders therapeutic - AMRI/Bristol-Myers SquibbAlternative Names: Triple reuptake inhibitor
Latest Information Update: 09 Sep 2016
At a glance
- Originator AMRI
- Developer AMRI; Bristol-Myers Squibb
- Mechanism of Action Biogenic amine uptake inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II CNS disorders
Most Recent Events
- 09 Sep 2016 CNS disorders therapeutic is still in phase II development for CNS disorders (AMRI pipeline, September 2016)
- 25 May 2011 Phase-II clinical trials in CNS disorders (unspecified route)